Hal Barron [File photo]
July 15, 2019 06:23 AM EDTUpdated 06:37 AM
R&D

Hal Bar­ron's team at GSK scores a win with pos­i­tive Ze­ju­la PhI­II front­line study — now comes the hard part

John Carroll

Editor & Founder

Score one for Hal Bar­ron and the new R&D team steer­ing Glax­o­SmithK­line’s pipeline.

The phar­ma gi­ant re­port­ed this morn­ing that its re­cent­ly ac­quired PARP …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bris­tol My­ers launch­es fresh round of ma­jor cost cuts in bid to get ahead of patent cliff

Lil­ly posts 45% sales jump, culls four pro­grams across obe­si­ty, Alzheimer's, heart fail­ure and eczema

As­traZeneca of­fers some de­tail on Chi­na probe, reaf­firms com­mit­ment to that mar­ket

No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says

Ku­ra's AML drug pass­es key study in ad­vanced pa­tients, plans next steps with FDA and new­ly di­ag­nosed stud­ies

Small per­son­al­ized vac­cine tri­al sees progress in late-stage kid­ney can­cer

A service from the Financial Times